Advertisement

SmartCells Inc., a Beverly diabetes drug developer, is to be acquired by Merck & Co. Inc. for a total of about $500 million, according to a news release today.

The transaction will bring SmartCells’ outstanding stock to Merck, while SmartCell shareholders will be given an upfront cash payment, plus potential development and regulatory milestone payments.

SOURCE

Advertisement
Advertisement